ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Invivo CAR-T

Its studies are mostly in Burkitt Lymphoma · Multiple Myeloma, led by Chongqing Precision Biotech.

Furthest: phase 1, since Nov 16, 20252 company-led studies, 2 open or runningNext primary completion: Dec 31, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Chongqing Precision Biotech22 open or runningphase 1since Nov 16, 2025Nov 16, 2025Dec 31, 2027phase 1 · NCT07239323

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 16, 2025First study: phase 1 study in Burkitt LymphomaFirst studyNCT07239323 · 24 planned · China
  2. Jul 14, 2026Phase 1 study in RecurrenceNCT07715630 · 15 planned · China

Ahead

  1. Dec 31, 2027Primary completion: phase 1 study in Burkitt LymphomaNCT07239323
  2. Apr 30, 2028Primary completion: phase 1 study in RecurrenceNCT07715630

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07715630Recurrence · China1RecruitingApr 30, 202815
NCT07239323Burkitt Lymphoma · China1RecruitingDec 31, 202724

How it is read

Names in the registry

  • “Invivo CAR-T”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.